# OnCo record volastra-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/volastra-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "volastra-therapeutics" ;
  schema:name "Volastra Therapeutics"@en ;
  schema:alternateName "Volastra Therapeutics, Inc."@en, "Volastra"@en ;
  schema:description "Volastra Therapeutics develops medicines taken by mouth, aimed at cancers whose cells keep making errors when they divide their chromosomes. Its two drugs block a protein called KIF18A and are in early trials, mainly in ovarian cancer."@en ;
  schema:url <https://onco.cc/companies/volastra-therapeutics/>, <https://www.volastratx.com/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.volastratx.com/>, <https://www.volastratx.com/pipeline/>, <https://www.volastratx.com/partnerships-and-deals/>, <https://www.volastratx.com/volastra-therapeutics-announces-biomarker-and-combination-data-around-aacr-2026-defining-an-rb-pathway-driven-pan-cancer-development-strategy-for-kif18a-inhibitors/>, <https://clinicaltrials.gov/study/NCT05902988>, <https://web.archive.org/web/20261016142320/https://www.archventure.com/portfolio/> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/high-grade-serous-ovarian-cancer/>, <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/synthetic-lethality-approaches/> ;
  onco:targets <https://onco.cc/targets/kif18a/> ;
  onco:drugs <https://onco.cc/drugs/vls-1488/>, <https://onco.cc/drugs/sovilnesib/> ;
  onco:trials <https://onco.cc/trials/nct05902988/> .